These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 8160445)
21. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529 [TBL] [Abstract][Full Text] [Related]
22. [Basic characteristics of a live influenza vaccine for children from type A influenza (H1N1 and H3N2) used separately and in combination]. Rudenko LG; Shvartsman IaS; Ispolatova AV; Grigor'eva EP; Drinevskiĭ VP Vopr Virusol; 1989; 34(1):29-34. PubMed ID: 2728404 [TBL] [Abstract][Full Text] [Related]
23. [The results of a study of the data obtained from patients vaccinated earlier with different influenza vaccines]. Ivanova VT; Slepushkin AN; Burtseva EI; Oskerko TA; Golubeva LI; Beliaev AL Vopr Virusol; 1994; 39(2):66-8. PubMed ID: 8017055 [TBL] [Abstract][Full Text] [Related]
24. [Seroconversion after vaccine with trivalent influenza vaccine during the epidemic season 1990/1 in Poland]. Brydak L; Rudnicka H; Gut W; Magdzik W; Kańtoch M Przegl Epidemiol; 1992; 46(3):221-9. PubMed ID: 1296247 [TBL] [Abstract][Full Text] [Related]
25. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737 [TBL] [Abstract][Full Text] [Related]
26. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Belshe R; Lee MS; Walker RE; Stoddard J; Mendelman PM Expert Rev Vaccines; 2004 Dec; 3(6):643-54. PubMed ID: 15606348 [TBL] [Abstract][Full Text] [Related]
27. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Murphy BR; Coelingh K Viral Immunol; 2002; 15(2):295-323. PubMed ID: 12081014 [No Abstract] [Full Text] [Related]
28. Influenza vaccines. Brede HD Int Arch Allergy Immunol; 1995 Dec; 108(4):318-20. PubMed ID: 7580301 [TBL] [Abstract][Full Text] [Related]
31. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. Hurwitz ES; Haber M; Chang A; Shope T; Teo ST; Giesick JS; Ginsberg MM; Cox NJ J Infect Dis; 2000 Oct; 182(4):1218-21. PubMed ID: 10979921 [TBL] [Abstract][Full Text] [Related]
32. Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components. Horimoto T; Iwatsuki-Horimoto K; Hatta M; Kawaoka Y Microbes Infect; 2004 May; 6(6):579-83. PubMed ID: 15158192 [TBL] [Abstract][Full Text] [Related]
33. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. Baldo V; Baldovin T; Floreani A; Fragapane E; Trivello R; J Clin Immunol; 2007 Sep; 27(5):542-7. PubMed ID: 17514499 [TBL] [Abstract][Full Text] [Related]
34. [A comparative study of the protective properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8- to 15-year-old children]. Burtseva EI; Obrosova-Serova NP; Govorkova EA; Rudenko LG; Vartanian RV; Beliaev AL; Ivanova VT; Musina MD; Cheshek SG; Zazimko LA Vopr Virusol; 1991; 36(5):375-7. PubMed ID: 1803767 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation of seroconversion after vaccination against influenza during the epidemic season 1991-1992 in Poland]. Brydak L; Rudnicka H Przegl Epidemiol; 1993; 47(3):275-83. PubMed ID: 8234846 [TBL] [Abstract][Full Text] [Related]
37. [Results of a study of new preparations of inactivated whole-virion influenza vaccines for the protection of children in the USSR]. Vasil'eva RI; Lonskaia NI; Nefedova LA; Iaroshevskaia IIu; Bichurina MA Zh Mikrobiol Epidemiol Immunobiol; 1987 Mar; (3):38-42. PubMed ID: 3591124 [TBL] [Abstract][Full Text] [Related]
38. Novel Platforms for the Development of a Universal Influenza Vaccine. Kumar A; Meldgaard TS; Bertholet S Front Immunol; 2018; 9():600. PubMed ID: 29628926 [TBL] [Abstract][Full Text] [Related]
39. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422 [TBL] [Abstract][Full Text] [Related]
40. [DEVELOPMENT OF THE QUADRIVALENT LIVE ATTENUATED INFLUENZA VACCINE INCLUDING TWO INFLUENZA B LINEAGES--VICTORIA AND YAMAGATA]. Desheva YA; Smolonogina TA; Doroshenko EM; Rudenko LG Vopr Virusol; 2016; 61(1):16-20. PubMed ID: 27145595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]